Literature DB >> 20975586

Allogeneic hematopoietic stem cell transplantation against recurrent rhabdomyosarcoma.

Hideaki Ohta1, Yoshiko Hashii, Hisao Yoshida, Shigenori Kusuki, Sadao Tokimasa, Akihiro Yoneda, Masahiro Fukuzawa, Nami Inoue, Junichi Hara, Takeshi Kusafuka, Keiichi Ozono.   

Abstract

The prognosis of high-risk rhabdomyosarcoma (RMS) with metastatic or recurrent disease remains poor. We report a 6-year-old girl who successfully underwent allogeneic hematopoietic stem cell transplantation against recurrent metastatic alveolar RMS. The disease recurred at distant lymph node metastasis with bone marrow involvement. After chemotherapy and radiotherapy for the metastatic site, she underwent allogeneic bone marrow transplantation during complete remission from her 5/8 HLA-matched father. She developed acute graft-versus-host disease after preemptive donor lymphocyte infusion and remains in a disease-free condition for 31 months after transplantation. A graft-versus-tumor effect through allogeneic immune cells might produce a beneficial effect for high-risk RMS.

Entities:  

Mesh:

Year:  2011        PMID: 20975586     DOI: 10.1097/MPH.0b013e3181e7ddc5

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.

Authors:  David R Shook; Brandon M Triplett; Ashok Srinivasan; Christine Hartford; Mari H Dallas; Asha Pillai; Joseph Laver; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-09       Impact factor: 5.742

2.  Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma.

Authors:  Sebastian J Schober; Irene von Luettichau; Angela Wawer; Maximilian Steinhauser; Christoph Salat; Wolfgang Schwinger; Marek Ussowicz; Petar Antunovic; Luca Castagna; Hans-Jochem Kolb; Stefan E G Burdach; Uwe Thiel
Journal:  Oncotarget       Date:  2018-04-27

Review 3.  Natural Killer Cells: Development, Maturation, and Clinical Utilization.

Authors:  Alex M Abel; Chao Yang; Monica S Thakar; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

4.  Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry.

Authors:  Hongqiang Shen; Yongmin Tang; Ao Dong; Huamei Li; Diying Shen; Shilong Yang; Hongfeng Tang; Weizhong Gu; Qiang Shu
Journal:  Oncol Lett       Date:  2014-02-04       Impact factor: 2.967

5.  Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.

Authors:  U Thiel; E Koscielniak; F Blaeschke; T G P Grunewald; M Badoglio; M A Diaz; C Paillard; A Prete; M Ussowicz; P Lang; F Fagioli; P Lutz; G Ehninger; P Schneider; A Santucci; P Bader; B Gruhn; M Faraci; P Antunovic; J Styczynski; W H Krüger; L Castagna; P Rohrlich; M Ouachée-Chardin; A Salmon; C Peters; M Bregni; S Burdach
Journal:  Br J Cancer       Date:  2013-10-22       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.